ANN ARBOR, MI--(Marketwire - October 03, 2007) - Pipex Pharmaceuticals, Inc. (“Pipex”) (AMEX: PP), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of neurologic and fibrotic diseases, announced today that it has received a $500,000 equipment loan from the Bank of Ann Arbor to support Pipex’s new cGMP pharmaceutical production facility which is primarily used for its lead product, COPREXA™ (oral tetrathiomolybdate) for neurologically-presenting Wilson’s disease and potential additional product candidates of Pipex.
